DK0690850T3 - 2-Substituerede morpholin- og thiomorpholinderivater som GABAB-antagonister - Google Patents

2-Substituerede morpholin- og thiomorpholinderivater som GABAB-antagonister

Info

Publication number
DK0690850T3
DK0690850T3 DK94911608.1T DK94911608T DK0690850T3 DK 0690850 T3 DK0690850 T3 DK 0690850T3 DK 94911608 T DK94911608 T DK 94911608T DK 0690850 T3 DK0690850 T3 DK 0690850T3
Authority
DK
Denmark
Prior art keywords
pct
formula
sec
date
substituted morpholine
Prior art date
Application number
DK94911608.1T
Other languages
Danish (da)
English (en)
Inventor
David J Blythin
William Kreutner
Shen-Chun Kuo
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK0690850T3 publication Critical patent/DK0690850T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/121,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings
    • C07F9/65335Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
DK94911608.1T 1993-03-26 1994-03-23 2-Substituerede morpholin- og thiomorpholinderivater som GABAB-antagonister DK0690850T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3858493A 1993-03-26 1993-03-26

Publications (1)

Publication Number Publication Date
DK0690850T3 true DK0690850T3 (da) 1998-02-09

Family

ID=21900746

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94911608.1T DK0690850T3 (da) 1993-03-26 1994-03-23 2-Substituerede morpholin- og thiomorpholinderivater som GABAB-antagonister

Country Status (14)

Country Link
US (1) US5929236A (https=)
EP (1) EP0690850B1 (https=)
JP (1) JP2778832B2 (https=)
AT (1) ATE160143T1 (https=)
AU (1) AU6408894A (https=)
CA (1) CA2158952C (https=)
DE (1) DE69406779T2 (https=)
DK (1) DK0690850T3 (https=)
ES (1) ES2109683T3 (https=)
GR (1) GR3025950T3 (https=)
IL (1) IL109111A (https=)
TW (1) TW280817B (https=)
WO (1) WO1994022843A1 (https=)
ZA (1) ZA942090B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009335A1 (en) * 1995-09-07 1997-03-13 Novartis Ag Substituted phosphinic compounds and their use as pharmaceuticals
AU5859598A (en) * 1996-12-24 1998-07-17 Novartis Ag (thio)morpholine-substituted carboxylic and phosphinic acids
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889857A (en) * 1987-10-12 1989-12-26 Yoshitomi Pharmaceutical Industries, Ltd. Quinolonecarboxylic acid compounds and pharmaceutical use thereof
NZ233503A (en) * 1989-05-15 1991-06-25 Janssen Pharmaceutica Nv Substituted (thio)morpholinyl and piperazinyl alkylphenol ethers
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法

Also Published As

Publication number Publication date
IL109111A (en) 1999-07-14
EP0690850A1 (en) 1996-01-10
DE69406779D1 (en) 1997-12-18
US5929236A (en) 1999-07-27
GR3025950T3 (en) 1998-04-30
IL109111A0 (en) 1994-06-24
JP2778832B2 (ja) 1998-07-23
DE69406779T2 (de) 1998-03-12
CA2158952C (en) 1999-05-18
CA2158952A1 (en) 1994-10-13
JPH08503229A (ja) 1996-04-09
ATE160143T1 (de) 1997-11-15
AU6408894A (en) 1994-10-24
ES2109683T3 (es) 1998-01-16
EP0690850B1 (en) 1997-11-12
TW280817B (https=) 1996-07-11
ZA942090B (en) 1994-09-26
WO1994022843A1 (en) 1994-10-13

Similar Documents

Publication Publication Date Title
MY140525A (en) Pharmaceutical uses for alpha2delta ligands
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
DK0527687T3 (da) Hidtil ukendte arylethylaminderivater, fremgansmåder til fremstilling heraf og farmaceutiske midler, som indeholder dem
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
DK0690850T3 (da) 2-Substituerede morpholin- og thiomorpholinderivater som GABAB-antagonister
ES2179996T3 (es) Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos.
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
RU94044454A (ru) Ингибитор аутоимунных заболеваний
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
PT838223E (pt) Inibidor do edema cerebral
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
TW244336B (https=)
MX9707596A (es) Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo.
BR9809313A (pt) Compostos, promedicamento, medicamento, processo para a sua preparação e utilização dos mesmos
ES2094638T3 (es) N-acilpirrolidinas y medicamentos para el tratamiento o la prevencion de los desordenes relacionados con la colecistoquinina y la gastrina.
ES2138017T3 (es) Uso de n-(piridinil)-1h-indol-1-aminas para la preparacion de un medicamento para el tratamiento de trastornos obsesivo-compulsivos.
KR950032194A (ko) 신규푸린유도체 및 그 약학적으로 허용되는 염
BR9306870A (pt) Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol
ES552193A0 (es) Un procedimiento para la preparacion de nuevos peptidos.
DK0632717T3 (da) Middel til anvendelse som et anti-irritationsmiddel
UA66751C2 (en) Benzamides as medicament for treatment of neurodegenerative state, a method for the preparation thereof (variants), pharnaceutical composition for treatment of neurodegenerative states and a method for treatment
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
SE9802546D0 (sv) Medicinal product and method for treatment and prevention of dyskinesia